English
Alpha Synuclein Oligomers (Dopamine HCL Stabilized)
Human Recombinant Alpha Synuclein Oligomers (Dopamine HCL Stabilized)
Artikelnummer
STRSPR-466E
Verpackungseinheit
100 µg x5
Hersteller
Stressmarq Biosciences
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Target: Alpha Synuclein.
Nature: Recombinant.
Swiss-Prot: P37840 .
Expression System: E. coli.
Protein Length: Full length.
Purification: Ion-exchange Purified. Monomeric alpha synuclein was removed via filtration.
Purity: >95%.
Storage Buffer: PBS pH 7.4.
Protein Size: ~14.46kDa.
Conjugate: No Tag.
Cellular Localization: Cytoplasm, Membrane, Nucleus.
Scientific Background: Alpha-Synuclein (SNCA) is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals (1). Alpha-synuclein is highly expressed in the mitochondria of the olfactory bulb, hippocampus, striatum and thalamus (2). Functionally, it has been shown to significantly interact with tubulin (3), and may serve as a potential microtubule-associated protein. It has also been found to be essential for normal development of the cognitive functions; inactivation may lead to impaired spatial learning and working memory (4). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimers disease amyloid plaque, and a major component of Lewy body inclusions, and Parkinson's disease. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin (5, 6). Dopamine inhibits alpha synuclein fibrillogenesis leading to oligomer accumulation in vitro (7), (8) and in vivo (9), (10).
References: 1. “Genetics Home Reference: SNCA”. US National Library of Medicine. (2013).2. Zhang L., et al. (2008) Brain Res. 1244: 40-52.3. Alim M.A., et al. (2002) J Biol Chem. 277(3): 2112-2117.4. Kokhan V.S., Afanasyeva M.A., Van'kin G. (2012) Behav. Brain. Res. 231(1): 226-230.5. Spillantini M.G., et al. (1997) Nature. 388(6645): 839-840.6. Mezey E., et al. (1998) Nat Med. 4(7): 755-757.7. Conway, K.A. et al. (2001) Science 294:1346-1349.8. Norris, E.H. et al. (2005) J Biol Chem. 280:21212-21219.9. Mazulli, J.R. et al. (2006). J Neurosci. 26:10068-10078.10. Mazulli, J.R. et al. (2007). J Biol Chem. 282:31621-31630.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.
Nature: Recombinant.
Swiss-Prot: P37840 .
Expression System: E. coli.
Protein Length: Full length.
Purification: Ion-exchange Purified. Monomeric alpha synuclein was removed via filtration.
Purity: >95%.
Storage Buffer: PBS pH 7.4.
Protein Size: ~14.46kDa.
Conjugate: No Tag.
Cellular Localization: Cytoplasm, Membrane, Nucleus.
Scientific Background: Alpha-Synuclein (SNCA) is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals (1). Alpha-synuclein is highly expressed in the mitochondria of the olfactory bulb, hippocampus, striatum and thalamus (2). Functionally, it has been shown to significantly interact with tubulin (3), and may serve as a potential microtubule-associated protein. It has also been found to be essential for normal development of the cognitive functions; inactivation may lead to impaired spatial learning and working memory (4). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimers disease amyloid plaque, and a major component of Lewy body inclusions, and Parkinson's disease. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin (5, 6). Dopamine inhibits alpha synuclein fibrillogenesis leading to oligomer accumulation in vitro (7), (8) and in vivo (9), (10).
References: 1. “Genetics Home Reference: SNCA”. US National Library of Medicine. (2013).2. Zhang L., et al. (2008) Brain Res. 1244: 40-52.3. Alim M.A., et al. (2002) J Biol Chem. 277(3): 2112-2117.4. Kokhan V.S., Afanasyeva M.A., Van'kin G. (2012) Behav. Brain. Res. 231(1): 226-230.5. Spillantini M.G., et al. (1997) Nature. 388(6645): 839-840.6. Mezey E., et al. (1998) Nat Med. 4(7): 755-757.7. Conway, K.A. et al. (2001) Science 294:1346-1349.8. Norris, E.H. et al. (2005) J Biol Chem. 280:21212-21219.9. Mazulli, J.R. et al. (2006). J Neurosci. 26:10068-10078.10. Mazulli, J.R. et al. (2007). J Biol Chem. 282:31621-31630.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.
| Artikelnummer | STRSPR-466E |
|---|---|
| Hersteller | Stressmarq Biosciences |
| Hersteller Artikelnummer | SPR-466E |
| Green Labware | Nein |
| Verpackungseinheit | 100 µg x5 |
| Mengeneinheit | PAK |
| Reaktivität | Human |
| Methode | Western Blotting, In Vivo Assay, SDS-PAGE |
| Human Gene ID | 6622 |
| Produktinformation (PDF) |
|
| MSDS (PDF) | Download |
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
